Developed by Ozkumur et al. [27], this hybrid system captured both EpCAM-positive and EpCAM-negative cancer cells from blood, overcoming the limitations of traditional affinity-based CTC capture methods [27]. The gene discussed is EPCAM; the disease is cancer.